Nimmit Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 04-12-2024
- Paid Up Capital ₹ 2.50 M
as on 04-12-2024
- Company Age 24 Year, 14 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 9.30 M
as on 04-12-2024
- Revenue 10.56%
(FY 2022)
- Profit 8.84%
(FY 2022)
- Ebitda 277.39%
(FY 2022)
- Net Worth 18.80%
(FY 2022)
- Total Assets -14.38%
(FY 2022)
About Nimmit Pharmaceuticals
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹9.30 M.
Hitendra Lakhani and Himatlal Lakhani serve as directors at the Company.
- CIN/LLPIN
U24229MH2001PTC130261
- Company No.
130261
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Jan 2001
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Nimmit Pharmaceuticals Private Limited offer?
Nimmit Pharmaceuticals Private Limited offers a wide range of products and services, including Organic and Inorganic Solvents, Alcohol Solvents, Isopropyl Alcohol IPA, Diatomaceous Earth, Organic Compounds, Hydrazine Hydrate, Propanol, Aromatic Hydrocarbon Solvent, Toluene, Plastic Granules.
Who are the key members and board of directors at Nimmit Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Hitendra Lakhani  | Director | 01-Jan-2001 | Current |
| Himatlal Lakhani | Director | 01-Jan-2001 | Current |
Financial Performance of Nimmit Pharmaceuticals.
Nimmit Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 10.56% increase. The company also saw a slight improvement in profitability, with a 8.84% increase in profit. The company's net worth Soared by an impressive increase of 18.8%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nimmit Pharmaceuticals?
In 2021, Nimmit Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of Baroda Creation Date: 10 May 2002 | ₹9.30 M | Open |
How Many Employees Work at Nimmit Pharmaceuticals?
Unlock and access historical data on people associated with Nimmit Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nimmit Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nimmit Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
